Syngenta Crop Protection has secured global patent protection for its advanced fungicides, Benzovindiflupyr (Solatenol) and Pydiflumetofen, bolstering its position in the agricultural market. Both compounds are part of Syngenta’s efforts to expand its portfolio of effective crop protection solutions against fungal diseases.
Benzovindiflupyr:
Benzovindiflupyr, is a potent fungicide classified within the dehydrogenase inhibitor (SDHI) pyrazole-carboxamide class, which belongs to the Fungicide Resistance Action Committee (FRAC) Group 7. This class of fungicides inhibits a key enzyme responsible for fungal respiration, effectively controlling a range of fungal pathogens.
Syngenta’s product patent for Benzovindiflupyr is set to expire on October 23, 2026, with the exception of countries where patent extensions are granted. In addition to the product patent, Syngenta has also filed multiple patents related to the process, method of use (MOU), and combination formulations of Benzovindiflupyr to further protect its intellectual property and market position.
Pydiflumetofen:
Pydiflumetofen is the newest member of the SDHI fungicide family, also falling under FRAC Group 7. It works by inhibiting succinate dehydrogenase, an enzyme critical for the production of energy in fungal cells, targeting diseases such as Fusarium, Cercospora, Botrytis, and Alternaria.
Syngenta has filed global patents for Pydiflumetofen, with the product patent set to expire on December 1, 2029, subject to extensions in specific countries. Like Benzovindiflupyr, Syngenta has also secured additional patents for Pydiflumetofen’s process, method of use, and combinations to strengthen its intellectual property protection.
Global Patent Status and Market Implications:
Syngenta’s recent patent declarations reveal that generic versions of Benzovindiflupyr will not be permitted on the market until its product patent expires, which is set to conclude in 2026 in most countries. Likewise, Pydiflumetofen will retain patent protection until 2029, restricting the introduction of generic alternatives until that year.
This protection also extends to any combination formulations of Benzovindiflupyr and Pydiflumetofen fungicides, maintaining exclusivity in the market for these products until their respective patent expirations.
Some markets may have additional protections such as Patent Term Extension and Supplementary Protection Certificate (SPC), which may extend the patent expiry for more time.
Implications for the Indian Market:
Benzovindiflupyr and Pydiflumetofen are currently approved in India, both as solo products and in combination, under Syngenta India. The patent landscape for these products includes compound, formulation, and mixture patents, along with their respective expiration dates. As a result, generic manufacturers will not be able to introduce a generic version of Benzovindiflupyr until 2026, and Pydiflumetofen until 2029.
For more details, visit and get access today at www.ChemRobotics.com